SMI
13.502,88
PKT
+56,45
PKT
+0,42
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SMI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 30.11.12 | Holcim equal-weight | Morgan Stanley | |
| 30.11.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 30.11.12 | Zurich Insurance hold | Vontobel Research | |
| 30.11.12 | Zurich Insurance outperform | Sanford C. Bernstein and Co., Inc. | |
| 29.11.12 | Swiss Life neutral | J.P. Morgan Cazenove | |
| 29.11.12 | Zurich Insurance neutral | Sarasin Research | |
| 29.11.12 | Swiss Life buy | Nomura | |
| 29.11.12 | Richemont buy | Sarasin Research | |
| 29.11.12 | Swiss Life buy | Vontobel Research | |
| 29.11.12 | Lonza hold | Vontobel Research | |
| 29.11.12 | Zurich Insurance hold | Vontobel Research | |
| 28.11.12 | UBS outperform | Credit Suisse Group | |
| 28.11.12 | Swiss Re neutral | Exane-BNP Paribas SA | |
| 28.11.12 | UBS overweight | J.P. Morgan Cazenove | |
| 28.11.12 | Swiss Life buy | Vontobel Research | |
| 28.11.12 | Swiss Life buy | Sarasin Research | |
| 27.11.12 | Nestlé kaufen | Hamburger Sparkasse AG (Haspa) | |
| 27.11.12 | Novartis kaufen | Hamburger Sparkasse AG (Haspa) | |
| 26.11.12 | Lonza hold | Vontobel Research | |
| 26.11.12 | Swiss Re neutral | Sarasin Research | |
| 26.11.12 | UBS neutral | Macquarie Research | |
| 26.11.12 | Swiss Re buy | Vontobel Research | |
| 26.11.12 | Richemont buy | Sarasin Research | |
| 23.11.12 | ABB (Asea Brown Boveri) outperform | Sanford C. Bernstein and Co., Inc. | |
| 22.11.12 | Zurich Insurance neutral | Credit Suisse Group | |
| 22.11.12 | Zurich Insurance neutral | J.P. Morgan Cazenove | |
| 22.11.12 | Holcim buy | UBS AG | |
| 22.11.12 | Holcim buy | UBS AG | |
| 22.11.12 | Swiss Life buy | UBS AG | |
| 22.11.12 | Holcim hold | Vontobel Research | |
| 21.11.12 | UBS overweight | Morgan Stanley | |
| 21.11.12 | Givaudan overweight | J.P. Morgan Cazenove | |
| 21.11.12 | Novartis reduce | Vontobel Research | |
| 20.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 20.11.12 | UBS neutral | Exane-BNP Paribas SA | |
| 20.11.12 | UBS outperform | Exane-BNP Paribas SA | |
| 20.11.12 | Holcim buy | Société Générale Group S.A. (SG) | |
| 20.11.12 | Novartis buy | Sarasin Research | |
| 20.11.12 | UBS neutral | Sarasin Research | |
| 20.11.12 | UBS hold | Vontobel Research |
* Die angezeigten Realtime Kurse sind indikativ und nicht die offiziellen Börsenkurse. Die Kursdaten können eventuell vom tatsächlichen Marktpreis abweichen.